Alzheimer's disease, the most common form of senile dementia, will impose a growing societal and healthcare burden as the population ages. With few treatments for symptomatic relief and unknown causes, more research is urgently needed. Psychedelic drugs target AD-related psychological pathology and symptoms such as depression. Through microdosing, they may help combat the disease by eliciting psychiatric benefits via serotonin and dopamine pathways. This review examines studied benefits of a few psychedelic compounds that may show promise in treating AD and attenuating its depressive symptoms. The putative mechanism of action is that psychedelics act mainly as serotonin receptor agonists and induce potential beneficial effects for treating AD and related depression.
Borderline personality disorder (BPD) involves impulsivity, emotional instability, and perceptual symptoms, and is often complicated by co-occurring conditions like depression. This case study describes ketamine-assisted psychotherapy (KAP) for a patient with both BPD and depression. KAP combines ketamine's antidepressant and psychedelic effects with psychotherapy, relying on the patient's inner healing intelligence and the therapist-patient relationship. Positive outcomes suggest that further systematic research into KAP for BPD and other personality disorders is warranted.